<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38611659</PMID><DateRevised><Year>2024</Year><Month>04</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-4418</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>30</Day></PubDate></JournalIssue><Title>Diagnostics (Basel, Switzerland)</Title><ISOAbbreviation>Diagnostics (Basel)</ISOAbbreviation></Journal><ArticleTitle>Incidence of Secondary Sclerosing Cholangitis in Hospitalized Long COVID-19 Patients: A Retrospective Single Center Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">745</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/diagnostics14070745</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">SARS-CoV-2 infection and associated COVID-19 disease can lead to critical illness with a risk of developing a multiple organ failure. Subsequently, this may lead to various pathological sequelae, such as secondary sclerosing cholangitis after surviving COVID-19 (SSC-COVID).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim is to retrospectively analyze a cohort of hospitalized patients with first-wave (February 2020-June 2020) SARS-CoV-2 infection and persisting unclear cholangiopathy to determine the incidence of SSC-COVID and its risk factors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 249 patients were hospitalized at the university hospital in T&#xfc;bingen, Germany, with SARS-CoV-2 infection during the first wave of the pandemic. Of these, 35.3% (88/249) required intensive care treatment; 16.5% (41/249) of them died due to the complications of COVID-19; 30.8% (64/208) of surviving patients could be followed up und were retrospectively analyzed at our center. The incidence of confirmed SSC-COVID was 7.8% (5/64). All SSC-COVID patients had an ICU stay &gt;20 days, for invasive ventilation, positioning treatment, vasopressor treatment, but possible risk factors for SSC were not significant due to the small number of patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">SSC-COVID is an emerging disease in post-COVID patients with a high incidence in our single-center cohort. SSC-COVID should be considered as a differential diagnosis, if unclear cholangiopathy or cholestasis persists after SARS-CoV-2 infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Werner</LastName><ForeName>Christoph R</ForeName><Initials>CR</Initials><Identifier Source="ORCID">0000-0001-8557-473X</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, Gastrointestinal Oncology, Hepatology, Infectious Diseases and Geriatrics, University Hospital T&#xfc;bingen, Otfried-M&#xfc;ller-Strasse 10, 72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fusco</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6093-4567</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, Gastrointestinal Oncology, Hepatology, Infectious Diseases and Geriatrics, University Hospital T&#xfc;bingen, Otfried-M&#xfc;ller-Strasse 10, 72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kienzle</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Gastrointestinal Oncology, Hepatology, Infectious Diseases and Geriatrics, University Hospital T&#xfc;bingen, Otfried-M&#xfc;ller-Strasse 10, 72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xf6;bele</LastName><ForeName>Stefanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Medical Microbiology and Hygiene, University Hospital T&#xfc;bingen, 72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Artzner</LastName><ForeName>Kerstin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Gastrointestinal Oncology, Hepatology, Infectious Diseases and Geriatrics, University Hospital T&#xfc;bingen, Otfried-M&#xfc;ller-Strasse 10, 72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malek</LastName><ForeName>Nisar P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Gastrointestinal Oncology, Hepatology, Infectious Diseases and Geriatrics, University Hospital T&#xfc;bingen, Otfried-M&#xfc;ller-Strasse 10, 72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wichmann</LastName><ForeName>D&#xf6;rte</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-8832-5031</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, Gastrointestinal Oncology, Hepatology, Infectious Diseases and Geriatrics, University Hospital T&#xfc;bingen, Otfried-M&#xfc;ller-Strasse 10, 72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf6;pel</LastName><ForeName>Siri</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7666-4634</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, Gastrointestinal Oncology, Hepatology, Infectious Diseases and Geriatrics, University Hospital T&#xfc;bingen, Otfried-M&#xfc;ller-Strasse 10, 72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Diagnostics (Basel)</MedlineTA><NlmUniqueID>101658402</NlmUniqueID><ISSNLinking>2075-4418</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">SSC</Keyword><Keyword MajorTopicYN="N">incidence</Keyword><Keyword MajorTopicYN="N">long COVID syndrome</Keyword><Keyword MajorTopicYN="N">retrospective observational study</Keyword><Keyword MajorTopicYN="N">secondary sclerosing cholangitis</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>13</Day><Hour>10</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>13</Day><Hour>10</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>13</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38611659</ArticleId><ArticleId IdType="pmc">PMC11011916</ArticleId><ArticleId IdType="doi">10.3390/diagnostics14070745</ArticleId><ArticleId IdType="pii">diagnostics14070745</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Atri D., Siddiqi H.K., Lang J.P., Nauffal V., Morrow D.A., Bohula E.A. COVID-19 for the Cardiologist: Basic Virology, Epidemiology, Cardiac Manifestations, and Potential Therapeutic Strategies. JACC Basic Transl. Sci. 2020;5:518&#x2013;536. doi: 10.1016/j.jacbts.2020.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacbts.2020.04.002</ArticleId><ArticleId IdType="pmc">PMC7151394</ArticleId><ArticleId IdType="pubmed">32292848</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzik T.J., Mohiddin S.A., Dimarco A., Patel V., Savvatis K., Marelli-Berg F.M., Madhur M.S., Tomaszewski M., Maffia P., D&#x2019;Acquisto F., et al. COVID-19 and the cardiovascular system: Implications for risk assessment, diagnosis, and treatment options. Cardiovasc. Res. 2020;116:1666&#x2013;1687. doi: 10.1093/cvr/cvaa106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvaa106</ArticleId><ArticleId IdType="pmc">PMC7197627</ArticleId><ArticleId IdType="pubmed">32352535</ArticleId></ArticleIdList></Reference><Reference><Citation>Puelles V.G., Lutgehetmann M., Lindenmeyer M.T., Sperhake J.P., Wong M.N., Allweiss L., Chilla S., Heinemann A., Wanner N., Liu S., et al. Multiorgan and Renal Tropism of SARS-CoV-2. N. Engl. J. Med. 2020;383:590&#x2013;592. doi: 10.1056/NEJMc2011400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2011400</ArticleId><ArticleId IdType="pmc">PMC7240771</ArticleId><ArticleId IdType="pubmed">32402155</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavriatopoulou M., Korompoki E., Fotiou D., Ntanasis-Stathopoulos I., Psaltopoulou T., Kastritis E., Terpos E., Dimopoulos M.A. Organ-specific manifestations of COVID-19 infection. Clin. Exp. Med. 2020;20:493&#x2013;506. doi: 10.1007/s10238-020-00648-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-020-00648-x</ArticleId><ArticleId IdType="pmc">PMC7383117</ArticleId><ArticleId IdType="pubmed">32720223</ArticleId></ArticleIdList></Reference><Reference><Citation>Klejtman T. Skin and COVID-19. J. Med. Vasc. 2020;45:175&#x2013;176. doi: 10.1016/j.jdmv.2020.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdmv.2020.06.001</ArticleId><ArticleId IdType="pmc">PMC7304393</ArticleId><ArticleId IdType="pubmed">32571556</ArticleId></ArticleIdList></Reference><Reference><Citation>Matschke J., Lutgehetmann M., Hagel C., Sperhake J.P., Schroder A.S., Edler C., Mushumba H., Fitzek A., Allweiss L., Dandri M., et al. Neuropathology of patients with COVID-19 in Germany: A post-mortem case series. Lancet Neurol. 2020;19:919&#x2013;929. doi: 10.1016/S1474-4422(20)30308-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30308-2</ArticleId><ArticleId IdType="pmc">PMC7535629</ArticleId><ArticleId IdType="pubmed">33031735</ArticleId></ArticleIdList></Reference><Reference><Citation>Lisco G., De Tullio A., Stragapede A., Solimando A.G., Albanese F., Capobianco M., Giagulli V.A., Guastamacchia E., De Pergola G., Vacca A., et al. COVID-19 and the Endocrine System: A Comprehensive Review on the Theme. J. Clin. Med. 2021;10:2920. doi: 10.3390/jcm10132920.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10132920</ArticleId><ArticleId IdType="pmc">PMC8269331</ArticleId><ArticleId IdType="pubmed">34209964</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang S., Wang R., Li L., Hong D., Ru R., Rao Y., Miao J., Chen N., Wu X., Ye Z., et al. Liver Injury in Critically Ill and Non-critically Ill COVID-19 Patients: A Multicenter, Retrospective, Observational Study. Front. Med. 2020;7:347. doi: 10.3389/fmed.2020.00347.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.00347</ArticleId><ArticleId IdType="pmc">PMC7324794</ArticleId><ArticleId IdType="pubmed">32656222</ArticleId></ArticleIdList></Reference><Reference><Citation>Alqahtani S.A., Schattenberg J.M. Liver injury in COVID-19: The current evidence. United Eur. Gastroenterol. J. 2020;8:509&#x2013;519. doi: 10.1177/2050640620924157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2050640620924157</ArticleId><ArticleId IdType="pmc">PMC7268949</ArticleId><ArticleId IdType="pubmed">32450787</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber S., Hellmuth J.C., Scherer C., Muenchhoff M., Mayerle J., Gerbes A.L. Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection: A prospective cohort study. Gut. 2021;70:1925&#x2013;1932. doi: 10.1136/gutjnl-2020-323800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-323800</ArticleId><ArticleId IdType="pmc">PMC7852072</ArticleId><ArticleId IdType="pubmed">33514597</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards K., Allison M., Ghuman S. Secondary sclerosing cholangitis in critically ill patients: A rare disease precipitated by severe SARS-CoV-2 infection. BMJ Case Rep. 2020;13:e237984. doi: 10.1136/bcr-2020-237984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2020-237984</ArticleId><ArticleId IdType="pmc">PMC7654135</ArticleId><ArticleId IdType="pubmed">33168538</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth N.C., Kim A., Vitkovski T., Xia J., Ramirez G., Bernstein D., Crawford J.M. Post-COVID-19 Cholangiopathy: A Novel Entity. Am. J. Gastroenterol. 2021;116:1077&#x2013;1082. doi: 10.14309/ajg.0000000000001154.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000001154</ArticleId><ArticleId IdType="pubmed">33464757</ArticleId></ArticleIdList></Reference><Reference><Citation>Durazo F.A., Nicholas A.A., Mahaffey J.J., Sova S., Evans J.J., Trivella J.P., Loy V., Kim J., Zimmerman M.A., Hong J.C. Post-Covid-19 Cholangiopathy-A New Indication for Liver Transplantation: A Case Report. Transplant. Proc. 2021;53:1132&#x2013;1137. doi: 10.1016/j.transproceed.2021.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transproceed.2021.03.007</ArticleId><ArticleId IdType="pmc">PMC7953456</ArticleId><ArticleId IdType="pubmed">33846012</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudnason H.O., Bjornsson E.S. Secondary sclerosing cholangitis in critically ill patients: Current perspectives. Clin. Exp. Gastroenterol. 2017;10:105&#x2013;111. doi: 10.2147/CEG.S115518.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CEG.S115518</ArticleId><ArticleId IdType="pmc">PMC5491618</ArticleId><ArticleId IdType="pubmed">28694703</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins P., Verdelho Machado M. Secondary Sclerosing Cholangitis in Critically Ill Patients: An Underdiagnosed Entity. GE Port. J. Gastroenterol. 2020;27:103&#x2013;114. doi: 10.1159/000501405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000501405</ArticleId><ArticleId IdType="pmc">PMC7113589</ArticleId><ArticleId IdType="pubmed">32266307</ArticleId></ArticleIdList></Reference><Reference><Citation>Faruqui S., Okoli F.C., Olsen S.K., Feldman D.M., Kalia H.S., Park J.S., Stanca C.M., Figueroa Diaz V., Yuan S., Dagher N.N., et al. Cholangiopathy After Severe COVID-19: Clinical Features and Prognostic Implications. Am. J. Gastroenterol. 2021;116:1414&#x2013;1425. doi: 10.14309/ajg.0000000000001264.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000001264</ArticleId><ArticleId IdType="pubmed">33993134</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasheed M.A., Ballotin V.R., Bigarella L.G., Soldera J. Post-COVID-19 cholangiopathy: Systematic review. World J. Methodol. 2023;13:296&#x2013;322. doi: 10.5662/wjm.v13.i4.296.</Citation><ArticleIdList><ArticleId IdType="doi">10.5662/wjm.v13.i4.296</ArticleId><ArticleId IdType="pmc">PMC10523251</ArticleId><ArticleId IdType="pubmed">37771872</ArticleId></ArticleIdList></Reference><Reference><Citation>Veerankutty F.H., Sengupta K., Vij M., Rammohan A., Jothimani D., Murali A., Rela M. Post-COVID-19 cholangiopathy: Current understanding and management options. World J. Gastrointest. Surg. 2023;15:788&#x2013;798. doi: 10.4240/wjgs.v15.i5.788.</Citation><ArticleIdList><ArticleId IdType="doi">10.4240/wjgs.v15.i5.788</ArticleId><ArticleId IdType="pmc">PMC10277943</ArticleId><ArticleId IdType="pubmed">37342848</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnstadt B., Zillinger C., Treitl M., Allescher H.D. Corona again? SSC after a severe COVID-disease. Z. Gastroenterol. 2021;59:1304&#x2013;1308. doi: 10.1055/a-1647-3785.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1647-3785</ArticleId><ArticleId IdType="pubmed">34666402</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonhardt S., Jurgensen C., Frohme J., Grajecki D., Adler A., Sigal M., Leonhardt J., Voll J.M., Kruse J.M., Korner R., et al. Hepatobiliary long-term consequences of COVID-19: Dramatically increased rate of secondary sclerosing cholangitis in critically ill COVID-19 patients. Hepatol. Int. 2023;17:1610&#x2013;1625. doi: 10.1007/s12072-023-10521-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12072-023-10521-0</ArticleId><ArticleId IdType="pmc">PMC10148013</ArticleId><ArticleId IdType="pubmed">37119516</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartl L., Haslinger K., Angerer M., Semmler G., Schneeweiss-Gleixner M., Jachs M., Simbrunner B., Bauer D.J.M., Eigenbauer E., Strassl R., et al. Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver disease. Hepatology. 2022;76:1563&#x2013;1575. doi: 10.1002/hep.32582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.32582</ArticleId><ArticleId IdType="pmc">PMC9347407</ArticleId><ArticleId IdType="pubmed">35596929</ArticleId></ArticleIdList></Reference><Reference><Citation>Butikofer S., Lenggenhager D., Wendel Garcia P.D., Maggio E.M., Haberecker M., Reiner C.S., Brullmann G., Buehler P.K., Gubler C., Mullhaupt B., et al. Secondary sclerosing cholangitis as cause of persistent jaundice in patients with severe COVID-19. Liver Int. 2021;41:2404&#x2013;2417. doi: 10.1111/liv.14971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/liv.14971</ArticleId><ArticleId IdType="pmc">PMC8242687</ArticleId><ArticleId IdType="pubmed">34018314</ArticleId></ArticleIdList></Reference><Reference><Citation>Pena-Perez C.A., Diaz Ponce-Medrano J.A. Secondary sclerosing cholangitis in critically ill patients. Cir. Cir. 2018;86:56&#x2013;62. doi: 10.24875/CIRU.M18000003.</Citation><ArticleIdList><ArticleId IdType="doi">10.24875/CIRU.M18000003</ArticleId><ArticleId IdType="pubmed">29681633</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelbmann C.M., Rummele P., Wimmer M., Hofstadter F., Gohlmann B., Endlicher E., Kullmann F., Langgartner J., Scholmerich J. Ischemic-like cholangiopathy with secondary sclerosing cholangitis in critically ill patients. Am. J. Gastroenterol. 2007;102:1221&#x2013;1229. doi: 10.1111/j.1572-0241.2007.01118.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2007.01118.x</ArticleId><ArticleId IdType="pubmed">17531010</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonhardt S., Veltzke-Schlieker W., Adler A., Schott E., Hetzer R., Schaffartzik W., Tryba M., Neuhaus P., Seehofer D. Trigger mechanisms of secondary sclerosing cholangitis in critically ill patients. Crit. Care. 2015;19:131. doi: 10.1186/s13054-015-0861-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-015-0861-5</ArticleId><ArticleId IdType="pmc">PMC4407292</ArticleId><ArticleId IdType="pubmed">25886728</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.Y., Lee S.S. Post-COVID-19 Cholangiopathy: Clinical and Radiologic Findings. Korean J. Radiol. 2023;24:1167&#x2013;1171. doi: 10.3348/kjr.2023.0832.</Citation><ArticleIdList><ArticleId IdType="doi">10.3348/kjr.2023.0832</ArticleId><ArticleId IdType="pmc">PMC10613835</ArticleId><ArticleId IdType="pubmed">37899526</ArticleId></ArticleIdList></Reference><Reference><Citation>Keta-Cov research group Intravenous ketamine and progressive cholangiopathy in COVID-19 patients. J. Hepatol. 2021;74:1243&#x2013;1244. doi: 10.1016/j.jhep.2021.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2021.02.007</ArticleId><ArticleId IdType="pmc">PMC7893247</ArticleId><ArticleId IdType="pubmed">33617925</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunyady P., Streller L., Ruther D.F., Groba S.R., Bettinger D., Fitting D., Hamesch K., Marquardt J.U., Mucke V.T., Finkelmeier F., et al. Secondary Sclerosing Cholangitis Following Coronavirus Disease 2019 (COVID-19): A Multicenter Retrospective Study. Clin. Infect. Dis. 2023;76:e179&#x2013;e187. doi: 10.1093/cid/ciac565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac565</ArticleId><ArticleId IdType="pmc">PMC9278244</ArticleId><ArticleId IdType="pubmed">35809032</ArticleId></ArticleIdList></Reference><Reference><Citation>Cesar Machado M.C., Filho R.K., El Bacha I.A.H., de Oliveira I.S., Ribeiro C.M.F., de Souza H.P., Parise E.R. Post-COVID-19 Secondary Sclerosing Cholangitis: A Rare but Severe Condition with no Treatment Besides Liver Transplantation. Am. J. Case Rep. 2022;23:e936250. doi: 10.12659/AJCR.936250.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/AJCR.936250</ArticleId><ArticleId IdType="pmc">PMC9394546</ArticleId><ArticleId IdType="pubmed">35978523</ArticleId></ArticleIdList></Reference><Reference><Citation>Kundrotas L.W., Clement D.J. Serum alanine aminotransferase (ALT) elevation in asymptomatic US Air Force basic trainee blood donors. Dig. Dis. Sci. 1993;38:2145&#x2013;2150. doi: 10.1007/BF01299887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01299887</ArticleId><ArticleId IdType="pubmed">8261813</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>